We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Recently published data suggest a rapid clearance of antibodies after recovery from SARS-CoV-2 infection. This article reports experience of 34 patients from the University of California in Los Angeles with confirmed COVID-19 whose serial antibody titers (ranging 44–119 days) were monitored. The researchers demonstrated an antibody half-life of 36 days over an observation period of approximately 90 days.
With these data, it does not appear that durable humoral immunity is achieved after SARS-CoV-2 infection. These data need to be carefully considered as the world rushes to develop a vaccine and make public health policies for patients who are antibody-positive.
– Kolene E. Bailey, MD
This abstract is available on the publisher's site.
A recent article suggested the rapid decay of anti–SARS-CoV-2 IgG in early infection, but the rate was not described in detail. We evaluated persons who had recovered from Covid-19 and referred themselves to our institution for observational research. Written informed consent was obtained from all the participants, with approval by the institutional review board. Blood samples were analyzed by enzyme-linked immunosorbent assay (ELISA) to detect anti–SARS-CoV-2 spike receptor-binding domain IgG. The ELISA was further modified to precisely quantify serum anti–receptor-binding domain activity in terms of equivalence to the concentration of a control anti–receptor-binding domain monoclonal IgG (CR3022, Creative Biolabs).